Canonical 1946 sedating antihistamine, well-understood and thoroughly superseded on every therapeutic dimension
Look, diphenhydramine is almost the ideal negative example for what this library is supposed to surface. It was approved in 1946. It’s in Benadryl, ZzzQuil, Tylenol PM, and approximately every OTC sleep product on the drugstore shelf. The mechanism is textbook second-year pharmacology: potent H1 blockade (Ki ~16 nM) combined with broad muscarinic antagonism across M1-M5 (Ki ~70 nM). The sedation is a side effect that got marketed as a feature. Thats not a research hook, thats a liability someone repackaged.
The anticholinergic burden is the most scientifically active conversation around this compound right now, and the news is not good. The BEERS Criteria flag it explicitly as potentially inappropriate in older adults. Long-term use epidemiology associates it with meaningful dementia risk. The Anticholinergic Cognitive Burden scale uses it as a reference entry. So the “interesting” research angle here is essentially “how bad is this for brains” rather than any forward-looking therapeutic story.
On differentiation: second-generation antihistamines (cetirizine, fexofenadine, loratadine) were developed for the specific purpose of removing exactly what makes diphenhydramine problematic. They strip the CNS penetration, reduce the anticholinergic load, and retain the H1 efficacy. In allergy indications, the second-gen compounds are strictly better. Diphenhydramine survives as an OTC sleep aid because sleepiness is the desired endpoint there, not because it’s pharmacologically refined.
We’ll give it credit where it’s due: the evidence base is massive. Multiple approved indications, well-replicated pharmacokinetics (plasma half-life 4-8 hours, reasonable oral bioavailability), a clear human signal for its approved uses. But strong evidence for tired indications isn’t what this library tracks. What we care about is whether a serious investigator should spend time on it, and the answer is almost never unless they’re specifically studying anticholinergic burden mechanisms or running assay comparisons as a reference standard for H1 pharmacology.
The bench utility is real but narrow. It appears in receptor selectivity panels, ACB scoring research, and as a comparator in antihistamine profiling studies. Thats legitimate. It’s not the kind of indispensable probe that defines what’s possible in a research area. It’s more of a known quantity you include in a table to anchor your assay.
Honestly, the score of 30 probably feels generous given how thoroughly this compound has been superseded. The evidence quality axis pulls it up because 75 years of replicated pharmacology is hard to ignore. But novelty at 5 and mechanism at 12 are where the real story lives: this compound solved a problem in 1946 that was solved more elegantly by 1995. Research time is better spent elsewhere.